8-K: Surrozen Launches $50M At-The-Market Equity Offering

Surrozen, Inc. has entered into a sales agreement with TD Cowen to offer and sell up to $50 million of its common stock through an at-the-market offering.

Summary

• Entered into a Sales Agreement with TD Securities (USA) LLC (TD Cowen) on August 29, 2025, to establish an at-the-market (ATM) equity offering program.
• May offer and sell shares of common stock with an aggregate offering amount of up to $50.0 million.
• TD Cowen will act as the sales agent and/or principal, using commercially reasonable efforts to sell shares based on the Company's instructions.
• Sales methods include negotiated transactions (e.g., block trades) or at-the-market offerings on the Nasdaq Capital Market or other existing trading markets.
• The Company will pay TD Cowen a commission of up to 3.0% of the gross sales proceeds.
• The offering is conducted pursuant to the Company's Registration Statement on Form S-3 (File No. 333-287434), filed on May 20, 2025, and a prospectus supplement dated August 29, 2025.
• The Company is not obligated to sell any shares under the Sales Agreement.

Sentiment

Score: 7

Explanation: The establishment of an ATM facility provides the company with flexible access to capital, which is generally positive for liquidity and funding future operations. However, the potential for dilution and market-dependent execution introduces some uncertainty.

Positives

• Provides flexible access to up to $50.0 million in capital, enhancing the Company's financial liquidity and runway.
• The 'at-the-market' structure allows for opportunistic capital raises, enabling the Company to sell shares when market conditions are favorable and manage potential dilution over time.
• Leveraging an established financial institution like TD Cowen for distribution indicates market access and a structured approach to financing.

Negatives

• Potential for dilution of existing shareholders as new common stock is issued and sold into the market.
• Sales are subject to market conditions and TD Cowen's 'commercially reasonable efforts,' meaning there is no guarantee that the full $50 million will be raised or at optimal prices.
• A commission of up to 3.0% of gross sales proceeds will be paid to TD Cowen, reducing the net capital received by the Company.

Risks

• Market price fluctuations of the common stock could impact the amount of capital raised and the timing of sales, potentially leading to sales at lower prices.
• There is no assurance that TD Cowen will be successful in selling Placement Shares, which could limit the Company's ability to raise the desired capital.
• The Company's ability to raise capital is dependent on the continued effectiveness of its Registration Statement and ongoing compliance with SEC rules and Nasdaq listing requirements.
• The ongoing possibility of share sales under the ATM program could create an overhang on the stock, potentially contributing to price volatility.

Future Outlook

The Company intends to use the net proceeds from any sales of common stock as described in the 'Use of Proceeds' section of its Prospectus. The ATM facility provides a flexible mechanism for future capital raises, but no specific guidance on future financial performance, product development timelines, or market expectations is provided in this filing.

Industry Context

At-the-market offerings are a common and flexible financing tool for publicly traded companies, particularly in capital-intensive sectors like biotechnology and pharmaceuticals. This mechanism allows companies to raise capital incrementally to fund ongoing research and development, clinical trials, or general corporate purposes, adapting to market conditions without the immediate price impact of a large, fixed-price offering. This approach is often favored by companies seeking to manage their cash burn rate and extend their operational runway.

Comparison to Industry Standards

• The commission rate of up to 3.0% payable to TD Cowen is consistent with typical fees for at-the-market equity offerings, which generally range from 1% to 3% depending on the company's market capitalization, trading liquidity, and the agent's services.
• The maximum offering amount of $50 million is a common size for ATM programs for small to mid-cap companies seeking to provide a capital buffer or fund specific initiatives over time.
• The use of a Form S-3 registration statement is standard for eligible public companies, allowing for efficient and flexible capital raises compared to other registration forms.

Stakeholder Impact

• Shareholders: Face potential dilution from the issuance of new common stock, which could impact per-share earnings and ownership percentage. However, enhanced company liquidity could support long-term growth and value creation.
• Company: Gains increased financial flexibility and a readily available source of capital to fund ongoing operations, research and development, or other strategic initiatives without the need for a traditional, more time-consuming offering.

Next Steps

• The Company may, at its discretion, issue Placement Notices to TD Cowen to initiate sales of common stock under the agreement.
• TD Cowen will use commercially reasonable efforts to sell shares based on the Company's instructions and market conditions.
• The Company will file prospectus supplements with the SEC for any sales made and will disclose sales in its quarterly and annual reports.

Key Dates

Recommendation

The establishment of an ATM facility provides financial flexibility, which is a positive for the company's operational runway. However, the potential for dilution and the lack of specific details on the immediate use of proceeds or strategic impact mean that investors should hold their positions and monitor the actual execution of the ATM program and future company announcements for more definitive signals. The offering itself is a financing mechanism, not a performance indicator of the company's current operations or future prospects.

Keywords

Surrozen, SRZN, At-The-Market Offering, ATM, Equity Offering, Capital Raise, Common Stock, TD Cowen, SEC Filing, Form S-3, Nasdaq Capital Market, Dilution, Biotechnology, Pharmaceutical